To study the effects of etanercept (TNF-blocker) on BMD and vertebral fractures in AS patients after two years of treatment. Additionally, changes in markers of bone turnover (CTXI, CTXII, RANKL, OPG, Osteocalcin) and radiological progression, including the thoracic spine, were studied during treatment with etanercept

Trial Profile

To study the effects of etanercept (TNF-blocker) on BMD and vertebral fractures in AS patients after two years of treatment. Additionally, changes in markers of bone turnover (CTXI, CTXII, RANKL, OPG, Osteocalcin) and radiological progression, including the thoracic spine, were studied during treatment with etanercept

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Feb 2016

At a glance

  • Drugs Etanercept
  • Indications Ankylosing spondylitis
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 15 Feb 2016 Results published in The Journal of Rheumatology
    • 15 Feb 2016 Primary endpoint "Bone mineral density (lumbar spine and hip)" has been met, as per the results published in The Journal of Rheumatology.
    • 02 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top